The Risk and Prevalence of COVID-19 Infection in Colorectal Cancer Patients: a Systematic Review and Meta-analysis

Abstract

Background Patients with cancer might be at an increased risk of infection with COVID-19 and a more severe disease course. However, different tumor types have differing susceptibility to the infection and COVID-19 phenotypes. Thus, the risk and prevalence of COVID-19 is not uniform across the different tumor types. Here, we performed a meta-analysis to estimate the risk and prevalence of COVID-19 infection in colorectal cancer (CRC) patients. Methods A comprehensive literature search was performed up to July 25, 2020, thorough PubMed, Web of Science, Scopus, Google Scholar, CNKI, CBM, China Science, Wan Fang, and SciELO databases. The risk of COVID-19 infection in CRC patients was performed based on the odds ratios (ORs) and 95% confidence interval (95% CI). Results A total of six studies with 204 different cancer patients with COVID-19 and 92 CRC infected patients with COVID-19 were selected. Our results showed that the prevalence of COVID-19 infection in CRC patients was 45.1% in the global population. The pooled data showed that there is no a significant risk of infection with COVID-19 in CRC patients in the global population (OR = 0.261, 95% CI 0.099-0.533, p = 0.082). However, when subgroup analysis was performed based on country of origin, we found a significant correlation in Chinese CRC patients (OR = 0.221, 95% CI 0.146-0.319, p ≤ 0.001). Conclusions This study results revealed that Chinese CRC patients harbored a higher risk of COVID-19 infection. However, more multicenter, larger sample sizes and high-quality studies are required to verify this meta-analysis result.

Proportion and mortality of Iranian diabetes mellitus, chronic kidney disease, hypertension and cardiovascular disease patients with COVID-19: a meta-analysis

“…Coronavirus disease 2019 (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has caused significant mortality and has been declared as a global pandemic by the World Health Organization [1][2][3][4][5]. COVID-19 is a major public health concern and one of the leading cause of mortality in most countries [6][7][8].…”

A novel multi-omics-based identification of symptoms, comorbid conditions, and possible long-term complications in COVID-19

“…In this analysis too, the viral infection is ranked one. The common comorbid conditions such as autoimmune disease (Rank-2) [50], vascular disease (Rank-4) [71], kidney disease (Rank-5) [56, 57], neurodegenerative disease (Rank-6) [72], bone inflammation disease (Rank-7) [73], myocardial disorder (Rank-7) [74], mood disorder (Rank-7) [34], breast cancer (Rank-10) [75], liver disease (Rank-10) [58], gynaecologic cancers (Rank-11) [76], asthma (Rank-12) [77], liver cancer (Rank-13) [78], musculoskeletal abnormality (Rank-14) [63], hematologic cancer (Rank-15) [79], retinal degeneration (Rank-15) [80], sepsis / septicaemia / septic shock (Rank-15) [60, 81], diabetes (Rank-16) [82], other cardiovascular diseases (Rank-17) [71, 74], viral encephalitis (Rank-17) [83], other cognitive disorder (Rank-18) [24], immunodeficiency (Rank-19) [84], brain disease (Rank-19) [85], COPD (Rank-19) [86], gastric / colon cancer (Rank-20) [87], autism (Rank-21) [88, 89], anemia (Rank-21) [90], bone development and degenerative disease (Rank-20) [91], dyslipidaemia (Rank-22) [92, 93], and ataxia (Rank-23) [94] etc. are among the top 25 child disease categories at a cut off score of 4 ( Fig-2B ).…”

“…Importantly, we observed a lot of cancers enriched in our analysis such as breast cancer (Rank-2), liver cancer (Rank-5), endometrial cancer (Rank-11), cervical cancer, ovarian cancer, nasopharyngeal carcinoma, prostate cancer (Rank-15), leukemia, colorectal cancer, melanoma, malignant germ cell tumor (Rank-16), chondroma (Rank-17), sarcoma, lymphoma, larynx cancer (Rank-18), esophagal cancer, pharynx cancer, squamous cell carcinoma of mouth (Rank-19) among others ( Fig-7B ). Considering our analysis that is showing high confidence in identifying the COVID-19 related conditions and complications, coupled with the facts that (i) some of these cancers such as breast cancer [75], liver cancer [78], gynaecologic cancers [76], hematologic [79], colon cancer [87], prostate cancer [115]are already reported as comorbid conditions, (ii) glioma may be developed due to COVID-19 [188], and the fact of viral carcinogenesis process[191, 192]; we hypothesize that the cancers we have identified in our analysis could be the long-term consequence of COVID-19.…”

Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis

“…The overall pooled prevalence of COVID-19 in ESRD patients with RRT was higher than the global average prevalence (3.1% vs. 0.1%)[3]. Moreover, the overall pooled prevalence of COVID-19 in ESRD patients with RRT was higher than that of autoimmune disease patients (3.10% vs. 1.1%)[52] but was lower than that of colorectal cancer patients (3.1% vs. 45.1%)[53]. The increased prevalence in ESRD patients might relate to decreased immunity from uremia[8].…”